Auris Medical Holding AG (NASDAQ:EARS) dropped 3.8% on Monday . The stock traded as low as $2.03 and last traded at $2.04, with a volume of 1,080,152 shares. The stock had previously closed at $2.12.

Several research analysts recently issued reports on EARS shares. Leerink Swann reissued a “buy” rating on shares of Auris Medical Holding AG in a research note on Thursday, May 12th. Jefferies Group reissued a “buy” rating on shares of Auris Medical Holding AG in a research note on Friday, June 10th. Zacks Investment Research raised Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price objective on the stock in a research note on Tuesday, July 12th. JMP Securities cut Auris Medical Holding AG from an “outperform” rating to a “market perform” rating in a research note on Thursday. Finally, Needham & Company LLC increased their price objective on Auris Medical Holding AG from $5.00 to $11.00 and gave the stock a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $8.88.

The stock’s 50 day moving average is $3.97 and its 200 day moving average is $3.93. The company’s market cap is $69.34 million.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.